ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate,hydrochloride

We are ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate,hydrochloride CAS:183322-17-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate,hydrochloride
CAS.NO:183322-17-0
Synonyms:Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate hydrochloride
2-Amino-4,5-bis(2-methoxyethoxy)benzoicacidethylesterhydrochloride
Molecular Formula:C15H24ClNO6
Molecular Weight:349.80700
 
Specification:
Appearance:Off-white powder
Purity(HPLC):≥99.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Erlotinib
 
Note:The product under valid patents will not be offered to the countries covered by patents.

ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate,hydrochloride


Related News: The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.6-bromo-1-hexanol CAS:4286-55-9 However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.4- [2- (Trimetilsilil) etoxicarboniloxi] nitrobenceno CAS:80149-80-0 However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.592-55-2 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.

Related Products
Product Name
3-Bromobenzotrifluoride View Details
10-Methoxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-one View Details
5-Chloro-2-(5-methyl-1,4-diazepan-1-yl)-1,3-benzoxazole View Details
L-pipecolate manufacturer 2-(Trifluoromethyl)thioxanthen-9-one manufacturer Diethyl 1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate Cas:1149-23-1 manufacturer hexamethyldisilazane manufacturer 6-Chloro-2-cyano-3-nitropyridine manufacturer